Inventaire - vos ami⋅e⋅s et communautés sont votre meilleure bibliothèque

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development

auteur·ice

James S McCarthy

Paul Griffin

Rob Hooft van Huijsduijnen

Stephan Duparc

Timothy N C Wells

Iñigo Angulo-Barturen

publié dans: Antimicrobial Agents and Chemotherapy

date de publication: 2016-04-04

langue: anglais

sujet principal: Plasmodium falciparum, antipaludéen

Articles cités 32

Date

Titre

Auteur·ices

2015-07-15

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Iñigo Angulo-Barturen, Maria Belen Jimenez-Diaz, Maria Lafuente-Monasterio, Clemens Kocken, Santiago Ferrer Bazaga, Maria Santos Martinez, Andrea Ruecker, Diana R. Tomchick, Vicky M. Avery, Susan A. Charman, David A. Fidock, Michael Delves, Sandra Duffy, Robert Sauerwein, Sergio Wittlin, Jeremy Burrows, Jon C. Mirsalis, Margaret A. Phillips, Pradipsinh K. Rathod, Farah El Mazouni, Didier Leroy, Julie Lotharius, Kennan Marsh, Karen White, Sreekanth Kokkonda, Francisco Javier Gamo Benito, Koen J Dechering, Hemangi Sharma, Thomas Rueckle, Robert E Sinden
2015-10-05

Hit and lead criteria in drug discovery for infectious diseases of the developing world

Rob Hooft van Huijsduijnen, Kiyoshi Kita, Charles E Mowbray, Jeremy Burrows
2015-08-03

How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?

Ian M Hastings, Katherine Kay, Eva Maria Hodel
2015-05-11

Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR

James S McCarthy
2014-09-30

Humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria

Thomas L. Richie
2014-01-01

Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.

Rachel E Sherman
2014-04-28

Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model.

Brioni R Moore, Kevin Batty, harmacy Practice
2013-06-06

Designing the next generation of medicines for malaria control and eradication

Rob Hooft van Huijsduijnen, Jeremy Burrows
2013

A new in vivo screening paradigm to accelerate antimalarial drug discovery

Iñigo Angulo-Barturen, José Francisco García-Bustos
2012-02

The role of animal models for research on severe malaria

Danny Milner, Alister G Craig, Jean Langhorne, Georges E Grau, Chris J Janse, James W Kazura
2012-10-04

Experimentally induced blood stage malaria infection as a tool for clinical research

Christian R. Engwerda, James S McCarthy
2011-08-22

A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs

James S McCarthy, Paul Griffin
2011-09-22

The parasite clearance curve

Nicholas White
2011-09-08

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity

Christian F Ockenhouse
2011-02-02

The relevance of non-human primate and rodent malaria models for humans

Pierre Buffet, Maria Manuel Dias da Mota, John T. Harty, Jean Langhorne, Eleanor Riley, Patrick E. Duffy, Michael F. Good, Laurent Rénia
2011-02-28

A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers

Michael D Nissen, Sarah J Tozer, Seweryn Bialasiewicz, David M Whiley
2011-01-01

Experimental human challenge infections can accelerate clinical malaria vaccine development

Robert W Sauerwein, Meta Roestenberg
2010-01-01

Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria

Stephen J. Rogerson, Steven R. Meshnick
2009-10

Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes

Iñigo Angulo-Barturen
2009-03-01

Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence.

Iñigo Angulo-Barturen
2008-05-21

A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes

Iñigo Angulo-Barturen, Philip J Rosenthal
2008-06-01

Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value

Philip Bejon, Adrian V. S. Hill
2007-09-29

Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects
2007-03-06

Malarial anemia: of mice and men.

Climent Casals-Pascual, Alexandre J. Potocnik, Jean Langhorne
2004-03-15

Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice
2000-12-01

Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance

Julie A. Simpson, Richard Price, Dennis E Kyle
1999-11-01

Population pharmacokinetics of mefloquine in patients with acute falciparum malaria

Feiko ter Kuile, Sornchai Looareesuwan, Nicholas White, François Nosten, Teja-Isavatharm P
1997-10-01

Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines.

Lisa C Ranford-Cartwright, Richard Carter
1993-03-01

Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy

Rex N. Brogden
1983-01-01

A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria
1983-01-01

A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand
1975-06-01

The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity

Article - wd:Q27324132

Bienvenue sur Inventaire

la bibliothèque de vos ami⋅e⋅s et communautés